We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · October 16, 2014

Circulating Proteins and Other Biomarkers for Sunitinib Efficacy in RCC

Cancer Chemotherapy and Pharmacology


Additional Info

Cancer Chemotherapy and Pharmacology
Investigation of Novel Circulating Proteins, Germ Line Single-Nucleotide Polymorphisms, and Molecular Tumor Markers as Potential Efficacy Biomarkers of First-Line Sunitinib Therapy for Advanced Renal Cell Carcinoma
Cancer Chemother. Pharmacol. 2014 Oct 01;74(4)739-750, RJ Motzer, TE Hutson, GR Hudes, RA Figlin, JF Martini, PA English, X Huang, O Valota, JA Williams

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading